Clinical TrialsAnalyst points out upcoming catalysts including the presentation of Phase 1 results for the company's VISTA-targeted mAb +/- Keytruda in advanced solid tumors.
Financial PositionTuHURA Biosciences ended the year with cash, cash equivalents, and marketable securities of approximately $12.7 million, which should be sufficient to fund operations into the fourth quarter of 2025.
Merger AcquisitionTuHURA gains full rights to Kineta's novel VISTA-targeted mAb, KVA12123 upon completion of the merger with Kineta, Inc.